Bristol Myers & J&J Halt Key Heart Drug Trial After Weak Results

Bristol Myers Squibb and Johnson & Johnson have stopped a major Phase 3 trial of milvexian for acute coronary syndrome after an interim review showed the drug is unlikely to meet its main goals. Other trials continue with results expected in 2026.